Login / Signup

Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study.

Laura VertechySerena Maria BocciaGiordana TiberiGiacomo AvesaniGiacomo CorradoAnna FagottiGiovanni ScambiaClaudia Marchetti
Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)
Pegylated liposomal doxorubicin/trabectedin might be an alternative option to platinum-based treatment in patients experiencing disease progression during PARP inhibitor maintenance with an acceptable toxicity profile. This might be a therapeutic option in this setting, sparing platinum compounds for subsequent relapse.
Keyphrases
  • dna damage
  • dna repair
  • drug delivery
  • cancer therapy
  • oxidative stress
  • recombinant human
  • minimally invasive
  • oxide nanoparticles